Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns

Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns

A large-scale registry study confirms that procainamide infusion is exceptionally safe for Brugada syndrome diagnosis, with high sensitivity and specificity. Crucially, asymptomatic patients with a procainamide-induced type 1 pattern demonstrate a very low risk of future arrhythmic events, potentially guiding more conservative management strategies.
High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry

High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry

The nationwide SCD‑PROTECT study (n=19,598) found substantial early risk of sustained VT/VF in newly diagnosed ischaemic and non‑ischaemic cardiomyopathy; wearable cardioverter‑defibrillators (WCDs) delivered life‑saving therapy with low inappropriate shock rates while ~52% recovered LVEF >35% during a mean 66‑day WCD period.